TUESDAY, Oct. 14, 2025 (HealthDay News) -- The incidence rates for invasive lobular carcinoma (ILC) increased from 2012 to 2021 for all racial and ethnic groups, according to a study published online ...

While the ductal subtype accounts for 70% to 80% of all breast cancers and the lobular subtype accounts for just 10% to 15%, the lobular subtype is more common among peri- and postmenopausal women, is ...

Rates of one type of breast cancer — invasive lobular carcinoma — have been rising in the United States more than three times faster than those of all other breast cancers combined over the past ...

Lobular breast cancer rates increased 2.8 percent per year over the past decade, compared with a 0.8 percent annual increase for all other breast cancers. Lobular breast cancer grows in a linear ...

Women with estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative invasive lobular carcinoma who are treated with endocrine therapy do not derive any additional ...

Invasive lobular carcinoma accounts for about 10% of breast cancer diagnoses. Its incidence is increasing at the rate of 2.8% annually -- more than triple that of other breast cancers combined. This ...

Dr. Schwartz answers the question: 'Difference between in situ breast cancers?' — -- Question: What is the difference between ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS)?

While researchers work to improve lobular breast cancer screening, innovative treatments are improving outcomes for patients with the condition, which is diagnosed in more than 40,000 Americans each ...